HIV wasting syndrome
diseaseOn this page
Summary
HIV wasting syndrome (MONDO:0005797) is a disease and 12 clinical trials. Top therapeutic interventions include megestrol acetate, dronabinol, and nandrolone decanoate. A subtype of HIV infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Prevalence: 1-5 / 10 000 (Europe) [Orphanet-validated]
- Phenotypes (HPO): 8
- Clinical trials: 12
Clinical features
Epidemiology
Prevalence records
1 prevalence record(s), Orphanet:
| Type | Class | Value | Geography | Validation |
|---|---|---|---|---|
| Point prevalence | 1-5 / 10 000 | 20 | Europe | Validated |
Signs & symptoms
Clinical features (HPO)
8 HPO clinical features (Orphanet curated; top 8 by frequency):
| HPO ID | Term | Frequency |
|---|---|---|
| HP:0001824 | Weight loss | Frequent (30-79%) |
| HP:0002024 | Malabsorption | Frequent (30-79%) |
| HP:0002039 | Anorexia | Frequent (30-79%) |
| HP:0002721 | Immunodeficiency | Frequent (30-79%) |
| HP:0003202 | Skeletal muscle atrophy | Frequent (30-79%) |
| HP:0004326 | Cachexia | Frequent (30-79%) |
| HP:0004395 | Malnutrition | Frequent (30-79%) |
| HP:0500012 | Abnormal gonadotropin-releasing hormone concentration | Frequent (30-79%) |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | HIV wasting syndrome |
| Mondo ID | MONDO:0005797 |
| EFO | EFO:0007312 |
| MeSH | D019247 |
| Orphanet | 90081 |
| UMLS | C0343755 |
| MedGen | 87476 |
| GARD | 0019122 |
| Is cancer (heuristic) | no |
Disease family
This is a subtype of HIV infectious disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › reproductive system disorder › sexually transmitted disease › viral sexually transmitted disease › HIV infectious disease › HIV wasting syndrome
Related subtypes (4): AIDS related complex, central nervous system AIDS arteritis, AIDS, congenital human immunodeficiency virus
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
0 approved, 1 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Somatropin | Phase 3 (in late-stage trials) |
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Megestrol Acetate, Testosterone Enanthate, Thalidomide.
Clinical trials & evidence
Clinical trials
Clinical trials: 12.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 4 |
| Not specified | 4 |
| PHASE1 | 2 |
| PHASE4 | 1 |
| PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00006167 | PHASE4 | COMPLETED | Nutrition Intervention in AIDS Wasting |
| NCT00489528 | PHASE3 | COMPLETED | Growth Hormone in the Treatment of HIV-Associated Wasting |
| NCT00000925 | PHASE2 | COMPLETED | A Study to Evaluate High Protein Supplementation in HIV-Positive Patients With Stable Weight Loss |
| NCT00001079 | PHASE2 | COMPLETED | A Study of Megestrol Acetate Alone or in Combination With Testosterone Enanthate Drug in the Treatment of HIV-Associated Weight Loss |
| NCT00002127 | PHASE2 | COMPLETED | A Phase II, Parallel Group, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Thalidomide in Reducing Weight Loss in Adults With HIV Wasting Syndrome |
| NCT00637572 | PHASE2 | COMPLETED | Evaluate Weight Gain Using 2 Different Formulations of Megestrol Acetate Oral Suspension for AIDS-related Weight Loss |
| NCT00000737 | PHASE1 | COMPLETED | A Phase I/II Study to Evaluate Single Agent and Combination Therapy With Megestrol Acetate and Dronabinol for the Treatment of HIV-Wasting Syndrome |
| NCT00000854 | PHASE1 | COMPLETED | A Study to Evaluate the Effect of Nandrolone Decanoate in Women With HIV-Associated Weight Loss |
| NCT00001077 | Not specified | COMPLETED | A Comparison of Two Caloric Supplements in the Prevention of Weight Loss in Patients With AIDS Who Take Daily Multivitamin and Mineral Supplements |
| NCT00002157 | Not specified | COMPLETED | Compassionate Use Study of Two Dose Levels of Thalidomide in Adults With HIV Wasting Syndrome |
| NCT00004664 | Not specified | COMPLETED | Randomized Placebo-Controlled Study of Aerobic Exercise and Resistance Training Plus Megestrol Acetate for HIV-Wasting |
| NCT00006064 | Not specified | COMPLETED | The Effect of Anti-HIV Treatment on Body Characteristics of HIV-Infected Children |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| MEGESTROL ACETATE | 4 | 4 |
| DRONABINOL | 4 | 1 |
| NANDROLONE DECANOATE | 4 | 1 |
| OXANDROLONE | 4 | 1 |
| TESTOSTERONE ENANTHATE | 4 | 1 |
| THALIDOMIDE | 4 | 1 |
| CHEMBL4567541 | 0 | 2 |
| CHEMBL426123 | 0 | 2 |
| CHEMBL4071215 | 0 | 2 |